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Do isolated cognitive relapses exist? Commentary
Aurélie Ruet
Cognitive impairment is frequent in patients with mul-
tiple sclerosis (PwMS). The cognitive deficits could 
worsen along the disease contributing to significant 
disability taking into account some heterogeneity 
among PwMS. However, the possibility of acute cog-
nitive change has been reported during relapse, which 
includes physical symptoms, with full or partial 
recovery.1–3 Besides, the concept proposed by Pardini 
et al.4 relating to ‘Isolated Cognitive Relapses’ (ICRs) 
– with no physical worsening – based on a transient 
decrease of the Symbol Digit Modalities Test (SDMT) 
in PwMS is debated. The SDMT assessing mainly 
information processing speed has been well validated 
in MS, and its clinically meaningful change has been 
proposed based on ecological endpoint.5 Nevertheless, 
Pardini et al.4 acknowledged some limitations con-
cerning the choice of this definition of ICRs only 
based on one neuropsychological (NP) assessment. 
They underlined that ICRs were not self-identified, 
but they highlighted the value of informant versions of 
the Multiple Sclerosis Neuropsychological Screening 
Questionnaire (MSNQ).6 Interestingly, Pardini et al.4 
also supported the clinical relevance of ICRs due to 
their association with cognitive daily functioning and 
further cognitive decline in PwMS.
Besides, Baldwin et al.7 emphasized that the data pub-
lished by Pardini et al.4 came from retrospective study 
with a small sample size. In fact, it could be unjustly 
concluded that ICRs do not exist, whereas they are 
simply under-recognized by both patients and physi-
cians. Indeed, one could also wonder whether neu-
rologists use some tools for identifying ICRs in 
practice. Importantly, baseline and follow-up relevant 
cognitive assessments are needed to be able to detect 
prospectively ICRs in clinical setting.
Moreover, cognitive impairment is driven by the cumu-
lative brain inflammation and the ongoing neurodegen-
eration. It is questionable concerning the mechanisms 
leading to ICRs. The occurrence of new MS lesions in 
key and relevant areas involved in cognitive functions 
has been proposed for supporting them.4 One could 
argue that the presence of active inflammation could 
also alter the efficiency of brain networks and synaptic 
functioning that could drive a decrease of acute cogni-
tive performance.8 The presence of gadolinium enhanc-
ing (Gd+) lesion is part of the definition of disease 
activity in MS, and has been used for supporting cogni-
tive relapse.4,9 But the presence of Gd+ lesions only 
means the breakdown of blood–brain barrier, and does 
not reflect all types of inflammation within the brain. 
Most of the new grey matter lesions relevant for cogni-
tion are not identified, as well as diffuse inflammation 
and microglial activation that are not visualized with 
conventional imaging.
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So as defended by Baldwin, no large data could sup-
port the attractive concept of ICRs. Further longitudi-
nal studies are required to confirm the presence and 
the relevance of ICRs in PwMS. This controversy 
underlines the absence of consensual definition of 
cognitive relapse, and highlights the importance of 
regular cognitive evaluations from the diagnosis of 
MS to the follow-up visits in clinical practice. These 
findings could help to disentangle this important 
question in the future, which could have prognostic 
and therapeutic implications for PwMS.
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